ADMA MENU

About ADMA

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA's lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was submitted to the FDA on July 31, 2015. The company has received U.S. Patent 9,107,906.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

ADMA is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 92.7 M 9.26625E+07 2,001 2001 0.0% 2.85486E-05 8 K 8266
UWM ProShares Ultra Russell2000 175.1 M 1.75075E+08 1,999 1999 0.0% 4.06872E-05 15 K 15277
DWAS Invesco DWA SmallCap Momentum ETF 225.1 M 2.251E+08 199 199 0.3% 0.00303 680 K 680464
ITOT iShares Core S&P Total U.S. Stock Market ETF 24.5 B 2.44501E+10 3,561 3561 0.0% 0 47 K 47388
IWC iShares Microcap ETF 812.4 M 8.12372E+08 1,387 1387 0.07% 0.0007 530 K 530442
IWM iShares Russell 2000 ETF 45.6 B 4.55937E+10 1,988 1988 0.01% 0.0001 5.0 M 4950020
IWN iShares Russell 2000 Value ETF 9.4 B 9.44781E+09 1,388 1388 0.0% 0 186 K 186212
IWO iShares Russell 2000 Growth ETF 9.2 B 9.19167E+09 1,154 1154 0.02% 0.0002 1.8 M 1790110
IWV iShares Russell 3000 ETF 9.9 B 9.92627E+09 2,885 2885 0.0% 0 78 K 78451